MCP-1, also known as CCL2, is a key inflammatory biomarker involved in kidney disease. It plays a crucial role in innate immunity and tissue inflammation, particularly in kidney-related conditions. MCP-1 promotes the infiltration of monocytes and macrophages, induces the migration and activation of lymphocytes and NK cells, and contributes to kidney inflammation. It is associated with various types of nephropathy, including primary, secondary, and hereditary kidney diseases. MCP-1 levels increase in response to kidney injury and are closely linked to the severity and progression of nephropathy. It has been studied in conditions such as crescentic glomerulonephritis, chronic glomerulonephritis, diabetic nephropathy, lupus nephritis, and autosomal dominant polycystic kidney disease (ADPKD). MCP-1 is also involved in the progression of kidney disease and can serve as a predictive biomarker for disease outcomes. In ADPKD, MCP-1 is associated with the accumulation of macrophages and the growth of renal cysts. In sickle cell kidney disease, elevated MCP-1 levels are linked to glomerular damage and oxidative stress. MCP-1 is a promising non-invasive biomarker for early detection and monitoring of kidney disease. It has been shown to have good stability and predictive value in various kidney diseases. However, its specificity and sensitivity are relatively low, and further research is needed to fully understand its role in kidney disease.MCP-1, also known as CCL2, is a key inflammatory biomarker involved in kidney disease. It plays a crucial role in innate immunity and tissue inflammation, particularly in kidney-related conditions. MCP-1 promotes the infiltration of monocytes and macrophages, induces the migration and activation of lymphocytes and NK cells, and contributes to kidney inflammation. It is associated with various types of nephropathy, including primary, secondary, and hereditary kidney diseases. MCP-1 levels increase in response to kidney injury and are closely linked to the severity and progression of nephropathy. It has been studied in conditions such as crescentic glomerulonephritis, chronic glomerulonephritis, diabetic nephropathy, lupus nephritis, and autosomal dominant polycystic kidney disease (ADPKD). MCP-1 is also involved in the progression of kidney disease and can serve as a predictive biomarker for disease outcomes. In ADPKD, MCP-1 is associated with the accumulation of macrophages and the growth of renal cysts. In sickle cell kidney disease, elevated MCP-1 levels are linked to glomerular damage and oxidative stress. MCP-1 is a promising non-invasive biomarker for early detection and monitoring of kidney disease. It has been shown to have good stability and predictive value in various kidney diseases. However, its specificity and sensitivity are relatively low, and further research is needed to fully understand its role in kidney disease.